APA

Andrikovics H., Nahajevszky S., Szilvási A., Bors A., Adám E., Kozma A., Kajtár B., Barta A., Poros A. & Tordai A. (20071030). First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts. : Hematological oncology.

Chicago

Andrikovics Hajnalka, Nahajevszky Sarolta, Szilvási Anikó, Bors András, Adám Emma, Kozma András, Kajtár Béla, Barta Anikó, Poros Anna and Tordai Attila. 20071030. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts. : Hematological oncology.

Harvard

Andrikovics H., Nahajevszky S., Szilvási A., Bors A., Adám E., Kozma A., Kajtár B., Barta A., Poros A. and Tordai A. (20071030). First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts. : Hematological oncology.

MLA

Andrikovics Hajnalka, Nahajevszky Sarolta, Szilvási Anikó, Bors András, Adám Emma, Kozma András, Kajtár Béla, Barta Anikó, Poros Anna and Tordai Attila. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts. : Hematological oncology. 20071030.